- 2024 - present
Founder and ModeratorGender-Specific and Overall Wellness/Burnout in Physicians
- 2024 - present
Principal InvestigatorTBCRC 062: STOP-HER2 Stopping Trastuzumab Outcomes in Patients with HER2+ Metastatic Breast Cancer (MBC)
- 2024 - present
Alliance Study Champion / Principal InvestigatorNRG-CC011 Cognitive Training for Cancer Related Cognitive Impairment: A Multi-Center Randomized Controlled Trial
- 2024 - present
Alliance Study Champion / Site Principal InvestigatorEA1211 DIRECT Trial
- 2024 - present
MemberTBCRC HER2+ Breast Cancer Working Group
- 2023
Advisory BoardBreast Cancer U.S. KOL (Seagen/Pfizer)
- 2023
ParticipantDatopotamab deruxtecan (Dato-DXd) Advisory Board (AstraZeneca)
- 2023
Invited ParticipantBreast International Group (BIG)-NCTN
- 2023 - present
Member, Clinical & Translational ResearcherMayo Clinic Comprehensive Cancer Center, Oncology Research Committee
- 2023 - present
Study Arm Chaperone/Principal InvestigatorISPY2.2 Trial (Amendment 35)
- 2022 - present
Steering Committee MemberAstraZeneca ENHERTU
- 2022 - present
MemberMayo Clinic Institutional Review Board (IRB)
- 2022 - present
Co-ChairMayo Clinic HER2+ Breast Cancer Working Group
- 2022 - present
Podcast HostAcademic and Community Clinical Research United (ACCRU)
- 2022 - present
Steering Committee MemberHER2CLIMB-05 Clinical Trial (NCT05132582)
- 2022 - present
Alliance Study ChampionEA1211, Interim FDG-PET CT for PreDIcting Response of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial concept
- 2021 - 2023
MemberNCI Breast Cancer Steering Committee, neoSTEEP Working Group
- 2021 - present
Grant ReviewerMayo Clinic Breast Cancer and Ovarian Cancer SPORE
- 2021 - present
Overall Study Chair and Principal InvestigatorA011801 (CompassHER2 RD), FDA Registration Trial
- 2021 - present
Principal InvestigatorTAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine in Advanced HER2+ Tumors
- 2021 - present
Study ChairAlliance for Clinical Trials in Oncology
- 2020 - 2022
Principal InvestigatorT-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Trial
- 2020 - present
InterviewerMayo Clinic Breast Oncology Surgical Fellowship
- 2020 - present
Alliance Study ChampionEA1181, (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
- 2020 - present
Steering Committee MemberSGNTUC-028: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
- 2020 - present
Principal InvestigatorSMX20-001: An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation
- 2019 - 2021
ASCO Trainee and Early Career Council, Career Conversations, MentorAmerican Society for Clinical Oncology (ASCO)
- 2019 - present
Principal InvestigatorTBCRC 022: A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
- 2017 - present
MemberMayo Clinic Women's Cancer Program
- 2017 - present
Breast Committee MemberAlliance for Clinical Trials in Oncology
- 2017 - 2021
Principal InvestigatorECTx: Minnelide 101 (MCR)- A Phase I, Multi-center, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide(TM) Capsules given alone or in combination with Protein-Bound Paclitaxel
- 2017 - 2020
Principal InvestigatorA Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
- 2017 - present
MemberMayo Clinic Comprehensive Cancer Center, Women's Cancer Program
- 2017 - present
Co-Principal InvestigatorPROMISE Trial (MC 1634)
- 2017 - present
Principal InvestigatorNRG-BR004, A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
- 2017 - present
MemberAlliance for Clinical Trials in Oncology
- 2016 - present
MemberAmerican Association for Cancer Research (AACR)
- 2016 - 2021
Principal InvestigatorI3Y-MC-JPBZ monarcHER: A Phase II, Randomized, Multicenter, 3-Arm, Open-label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab
- 2016 - 2021
Principal InvestigatorA Multicenter, Open-label, Phase II Study of Imprime PGG and Pembro in Subjects with Adv Melanoma Failing Treatment with CPI or TNBC Failing Front-line Chemo for Metastatic Disease / BT-CL-PGG-MEL/BCA-1621/MK3475 PN-545
- 2016 - 2019
Principal InvestigatorMPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC), A Phase II Open-label, Randomized Study of PARP Inhibition (Olaparib), Either Alone or in Combination with Anti-PDL1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
- 2016 - present
Principal InvestigatorS1416, Phase II Randomized Placebo-controlled Trial of Cisplatin with or without ABT-888 (Velparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
- 2014 - 2016
Medical Oncology Quality Assurance Committee memberNational Institutes of Health (NIH)
- 2014 - 2016
CCR-FYI Steering CommitteeNational Institutes of Health (NIH)
- 2013 - 2016
MemberThe Wild Geese Network of Irish Scientists in North America
- 2013 - 2016
ClinFelcom, NCI Clinical Fellows CommitteeNational Institutes of Health (NIH)
- 2010 - present
MemberEuropean Society of Medical Oncology (ESMO)
- 2010 - present
MemberAmerican Society for Clinical Oncology (ASCO)
- 2009 - 2012
MemberIrish Society of Medical Oncology (ISMO)
- 2008 - present
MemberRoyal College of Physicians of Ireland (RCPI)